Factors contributing to carboplatin blockade and interruption in its route of administration in paclitaxel-carboplatin therapy

被引:0
|
作者
Inoue, Motoki [1 ]
Nakadate, Kazuhiko [1 ]
Oosaki, Mami [2 ]
Shirota, Mikio [2 ]
Yasu, Takeo [1 ,2 ,3 ,4 ]
机构
[1] Meiji Pharmaceut Univ, Tokyo, Japan
[2] Tokyo Metropolitan Bokutoh Hosp, Dept Pharm, Tokyo, Japan
[3] Meiji Pharmaceut Univ, Bokutoh Hosp, Joint Res Ctr, Tokyo, Japan
[4] Meiji Pharmaceut Univ, Pharmaceut Educ & Res Ctr, Dept Med Therapy Res, 2 522 1 Noshio, Kiyose, Tokyo 2048588, Japan
来源
DRUG DISCOVERIES AND THERAPEUTICS | 2023年 / 17卷 / 03期
关键词
adsorption; catheters; scanning electron microscopy; syringe pushing force;
D O I
10.5582/ddt.2022.01121
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The interruption of anticancer infusion processes in patients undergoing chemotherapy may affect their quality of life and the efficacy and safety of the therapy. We experienced several interruptions of carboplatin infusion in multiple patients receiving paclitaxel-carboplatin combination therapy. Therefore, we investigated the causes of these interruptions. The filter and catheter surfaces were evaluated by scanning electron microscopy. Moreover, using a texture analyzer, the mechanical strengths of catheter-attached syringes were compared pre- and post-administration. We observed that the syringe pushing force requirement was higher following dripping failure. However, precipitates were not evident on the filter surfaces, regardless of the dripping failure route. In this case, some of the drug adhered to the catheters' surfaces and interrupted the carboplatin titration. Consequently, in patients receiving combination therapy with paclitaxel and carboplatin, and experiencing interruptions in carboplatin infusion, attention should be paid to the catheter.
引用
收藏
页码:214 / 216
页数:3
相关论文
共 50 条
  • [41] Randomized phase III study comparing paclical-carboplatin with paclitaxel-carboplatin in patients with recurrent platinum-sensitive epithelial ovarian cancer.
    Vergote, Ignace
    Brize, Arija
    Lisyanskaya, Alla Sergeevua
    Lichinitser, Mikhail
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [42] Lunchbox trial: A randomized phase III trial of Cisplatin and irradiation followed by Carboplatin and Paclitaxel vs. sandwich therapy of Carboplatin and Paclitaxel followed by irradiation then Carboplatin and Paclitaxel for advanced endometrial carcinoma
    Barlin, Joyce
    Mahar, Barbara
    Ata, Ashar
    Cormier, Beatrice
    Michelin, David
    Salani, Ritu
    Backes, Floor
    Levinson, Kimberly
    Cantrell, Leigh
    Weinberg, Lori
    Wagreich, Allison
    Savage, Duncan
    Gasson, Christian
    Denniston, Kyle
    Martin, Jovana
    McElrath, Timothy
    Timmins, Patrick
    GYNECOLOGIC ONCOLOGY, 2023, 176 : S63 - S64
  • [43] Feasibility and toxicity of weekly paclitaxel-carboplatin in 131 patients with pretreated and non-pretreated solid tumors
    D'Addario, G
    Morant, R
    Böhme, C
    Cerny, T
    ONKOLOGIE, 2002, 25 (02): : 152 - 157
  • [44] Secondary Hodgkin Lymphoma and MDS after Paclitaxel-Carboplatin Treatment in a Patient with Small Cell Lung Cancer
    Petrushevska, Marija
    Stavrdis, Irina Panovska
    Petrusevska, Gordana
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S322 - S323
  • [45] Consolidation docetaxel after paclitaxel-carboplatin chemotherapy in stage Ic-IV ovarian cancer.
    Matsumoto, R.
    Isonishi, S.
    Suzuki, M.
    Nagano, H.
    Takagi, K.
    Ochiai, K.
    Tanaka, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [46] Life-threatening Clostridium difficile-associated diarrhea induced by paclitaxel-carboplatin combination chemotherapy
    Yamazawa, K
    Kanno, H
    Seki, K
    Kuzuta, T
    Matsui, H
    Sekiya, S
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2001, 80 (08) : 768 - 769
  • [47] Toxicity and feasibility of paclitaxel-carboplatin (PC) weekly combination chemotherapy in patients with various solid tumours.
    Morant, R
    D'Addario, G
    Böhme, C
    Cerny, T
    ANNALS OF ONCOLOGY, 2000, 11 : 137 - 137
  • [48] An Open-Label, Randomized, Controlled Phase II Study of Paclitaxel-Carboplatin Chemotherapy With Necitumumab Versus Paclitaxel-Carboplatin Alone in First-Line Treatment of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer
    Spigel, David R.
    Luft, Alexander
    Depenbrock, Henrik
    Ramlau, Rodryg
    Khalil, Mazen
    Kim, Joo-Hang
    Mayo, Carlos
    Chao, Grace Yi
    Obasaju, Coleman
    Natale, Ronald
    CLINICAL LUNG CANCER, 2017, 18 (05) : 480 - 488
  • [49] THE MYELOTOXICITY OF CARBOPLATIN IS INFLUENCED BY THE TIME OF ITS ADMINISTRATION
    KERR, DJ
    LEWIS, C
    ONEIL, B
    LAWSON, N
    BLACKIE, RG
    NEWELL, DR
    BOXALL, F
    COX, J
    RANKIN, EM
    KAYE, SB
    HEMATOLOGICAL ONCOLOGY, 1990, 8 (01) : 59 - 63
  • [50] Veliparib with carboplatin and paclitaxel: factors predictive of favorable outcomes in NSCLC
    Reck, M.
    Ramalingam, S.
    Blais, N.
    Mazieres, J.
    Jones, M.
    Juhasz, E.
    Urban, L.
    Orlov, S.
    Barlesi, F.
    Kio, E.
    Keilholz, U.
    Qian, J.
    Qin, Q.
    Dziubinski, J.
    Nickner, C.
    Ansell, P.
    McKee, M.
    Giranda, V.
    Gorbunova, V.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S630 - S630